Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scienture HoldingsSCNX +0.43%43 3-Year Share Buyback Ratio is -301.90 as of Jun. 2026. GuruFocus rates SCNX with a GF Score™ of 43/100 and a GF Value™ of $0.52 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 446 Healthcare Providers & Services companies, Scienture Holdings ranks worse than 99.1% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Scienture Holdings's current 3-Year Share Buyback Ratio was -301.90%.
The historical rank and industry rank for Scienture Holdings's 3-Year Share Buyback Ratio or its related term are showing as below:
SCNX'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -604.1 Med: -15 Max: -0.8
Current: -301.9
During the past 13 years, Scienture Holdings's highest 3-Year Share Buyback Ratio was -0.80%. The lowest was -604.10%. And the median was -15.00%.
SCNX's 3-Year Share Buyback Ratio is ranked worse than 99.1% of 446
companies
in the Healthcare Providers & Services industry
Industry Median: -1.75
vs SCNX: -301.90
Scienture Holdings (NAS:SCNX) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Scienture Holdings 3-Year Share Buyback Ratio Related Terms
SCNX vs HEWA, BLMH, PMHS: 3-Year Share Buyback Ratio Comparison
For the Pharmaceutical Retailers subindustry, Scienture Holdings's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scienture Holdings 3-Year Share Buyback Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Scienture Holdings's 3-Year Share Buyback Ratio falls into.
Scienture Holdings 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -301.90 mean?
Scienture Holdings (SCNX) has a 3-Year Share Buyback Ratio of -301.90 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Scienture Holdings and its competitors. According to the industry distribution chart, Scienture Holdings ranks #442 out of 446 companies in the Healthcare Providers & Services industry, placing it in the top 99.1%.
Is Scienture Holdings' 3-Year Share Buyback Ratio too high?
Scienture Holdings' current 3-Year Share Buyback Ratio is -301.90. Based on the distribution chart, Scienture Holdings ranks #442 out of 446 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Scienture Holdings has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' 3-Year Share Buyback Ratio compare to HEWA and BLMH?
According to the Healthcare Providers & Services industry distribution chart, Scienture Holdings ranks #442 out of 446 companies for 3-Year Share Buyback Ratio. This places Scienture Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Healthcare Providers & Services company?
A good 3-Year Share Buyback Ratio depends on the Healthcare Providers & Services industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Scienture Holdings and its competitors. Scienture Holdings's current 3-Year Share Buyback Ratio is -301.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.52, compared to a current price of $0.46 — trading 11.7% below its estimated fair value. The current 3-Year Share Buyback Ratio is -301.90. Scienture Holdings' overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current 3-Year Share Buyback Ratio is -301.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scienture Holdings (SCNX) Overvalued in 2026?
Based on GuruFocus' analysis, Scienture Holdings stock appears to be undervalued.
The current stock price of $0.46 is trading 11.7% below its estimated GF Value™ of $0.52.
GuruFocus considers Scienture Holdings to be Modestly Undervalued.
Key valuation signals for SCNX:
3-Year Share Buyback Ratio: -301.90
GF Value™: $0.52 vs. price of $0.46 (11.7% below fair value)
No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
43GF Score
Get the complete analysis for SCNX
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNX has been successfully added to your 
